Liv.52 therapy in viral hepatitis
Banerjea, L.K., M.B.,B.S., M.S., Commandant, Sahu, N.N., M.B.,B.S., Medical Officer, Ray, S.S., M.B.,B.S., Medical Officer and Daljit Singh, Biochemist, BSF Base Hospital, Kadamtala, Siliguri, Darjeeling, North Bengal 734 433, India.
Rowland (1972) in his study on epidemiology of infectious hepatitis has said that persons of all races and all ages are susceptible to infectious hepatitis. In India, poor sanitary conditions along with lack of personal cleanliness and poor diet contribute to its spread. The disease causes a lot of morbidity and mortality amongst the affected population.
So far no specific treatment has been found for the disease. As rightly pointed out by Sherlock, “There have been no revolutionary advances in the treatment of viral hepatitis whether type A or B and the present supportive treatment has little effect in altering the course.”
An indigenous drug combination, Liv.52 marketed by The Himalaya Drug Co. has been reported to offer major benefits in such cases, which have been proved experimentally and clinically by various authors. The advantages are as follows:
Liv.52
— prevents hepatic damage
— promotes hepato-cellular repair and regeneration
— prevents hazardous sequelae
— stops nausea, vomiting and pruritus
— restores appetite and sense of well-being
— shortens the therapy by achieving early recovery.
Considering the facts it was proposed to conduct a clinical trial of Liv.52 in cases of viral hepatitis occurring amongst BSF personnel of West Bengal.
MATERIAL AND METHODS
The present study is based on 53 cases of viral hepatitis admitted to the BSF Base Hospital, Kadamtala between 1973 to 1976. The age group was 18 to 45 years. Out of the total of 53 cases, 30 cases treated with Liv.52 tablets alone comprised Group A and the rest of 23 cases treated with Vitamin B-Complex, Vitamin C and antibiotics and oral corticosteroids (in 10 cases only) comprised Group B, to serve as Control. The patients of both groups were kept on plenty of glucose and a low-fat diet till their serum bilirubin level fell below 1 mg%..
A detailed history was taken in all cases with special emphasis on nausea, vomiting, loss of appetite, pruritus, colour of stools and urine, abdominal pain and dyspeptic symptoms.
A thorough clinical examination was done in all cases, and the following points were noted specially : colour of conjunctiva and clinical assessment of jaundice, enlargement of liver, spleen and hepatic tenderness.
In all cases, besides routine blood and urine examination the following special laboratory investigations were carried out:
1. Serum bilirubin
2. Zinc sulphate turbidity
3. Serum alkaline phosphatase
4. Urobilinogen in urine.
The above biochemical tests were repeated after 2 weeks and then again after 4 weeks of therapy to determine the progress.
OBSERVATIONS
Our observations were as follows:
So far no specific treatment has been found for the disease. As rightly pointed out by Sherlock, “There have been no revolutionary advances in the treatment of viral hepatitis whether type A or B and the present supportive treatment has little effect in altering the course.”
An indigenous drug combination, Liv.52 marketed by The Himalaya Drug Co. has been reported to offer major benefits in such cases, which have been proved experimentally and clinically by various authors. The advantages are as follows:
Liv.52
— prevents hepatic damage
— promotes hepato-cellular repair and regeneration
— prevents hazardous sequelae
— stops nausea, vomiting and pruritus
— restores appetite and sense of well-being
— shortens the therapy by achieving early recovery.
Considering the facts it was proposed to conduct a clinical trial of Liv.52 in cases of viral hepatitis occurring amongst BSF personnel of West Bengal.
MATERIAL AND METHODS
The present study is based on 53 cases of viral hepatitis admitted to the BSF Base Hospital, Kadamtala between 1973 to 1976. The age group was 18 to 45 years. Out of the total of 53 cases, 30 cases treated with Liv.52 tablets alone comprised Group A and the rest of 23 cases treated with Vitamin B-Complex, Vitamin C and antibiotics and oral corticosteroids (in 10 cases only) comprised Group B, to serve as Control. The patients of both groups were kept on plenty of glucose and a low-fat diet till their serum bilirubin level fell below 1 mg%..
A detailed history was taken in all cases with special emphasis on nausea, vomiting, loss of appetite, pruritus, colour of stools and urine, abdominal pain and dyspeptic symptoms.
A thorough clinical examination was done in all cases, and the following points were noted specially : colour of conjunctiva and clinical assessment of jaundice, enlargement of liver, spleen and hepatic tenderness.
In all cases, besides routine blood and urine examination the following special laboratory investigations were carried out:
1. Serum bilirubin
2. Zinc sulphate turbidity
3. Serum alkaline phosphatase
4. Urobilinogen in urine.
The above biochemical tests were repeated after 2 weeks and then again after 4 weeks of therapy to determine the progress.
OBSERVATIONS
Our observations were as follows:
Symptomatology |
||
|
No. of cases |
Percentage |
Loss of appetite |
53 |
100.0% |
Fever |
21 |
39.6% |
Nausea |
49 |
92.4% |
Vomiting |
4 |
7.5% |
Pruritus |
1 |
1.9% |
Highly coloured urine |
53 |
100.0% |
Refference: http://www.himalayahealthcare.com/pdf_files/liv234.pdf
Copyrights © 2009 healthyliver.co.uk